The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.20
Ask: 5.30
Change: 0.05 (0.96%)
Spread: 0.10 (1.923%)
Open: 5.15
High: 5.25
Low: 5.10
Prev. Close: 5.20
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Mar 2011 14:57

London afternoon: Shares mark time

Footsie finished the morning clinging on to positive territory and not much changed over the lunch time trading session, with a mildly firmer start on Wall Street providing little additional impetus. Worries that Japanese carmakers may have to suspend production at their plants in China following t

Read more
28 Mar 2011 14:06

Weak German market hits sales at Allergy Therapeutics

Pharmaceutical firm Allergy Therapeutics reported broadly flat revenues and profits for the six months ended 31 December, as a result of weakness in its core German market. First half revenue was £27.4m, slightly higher than £27.3m in 2009. Weakness in the euro also had a £1.1m impact on turnover.

Read more
20 Sep 2010 14:41

Small caps: Allergy Therapeutics, Goldplat, Avacta

Hay fever treatment specialist Allergy Therapeutics posted an operating profit for the year to June of £1.5m (2009: loss £5.1m) and cut losses to £116,000 from £11.4m. "On the regulatory front, the submission in March 2009 of Pollinex Quattro Grass, our ultra-short course four injection grass alle

Read more
22 Jul 2010 12:36

Allergy Therapeutics Sees FY Revenue GBP40.7M, Operating Profit

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN), a specialist pharmaceutical company focused on allergy vaccination, said Thursday, it expects to report revenue of GBP40.7 million, and an operating profit, for the year ended June 30, adding that the results was in-line with current market expe

Read more
1 Jul 2010 16:00

UK SMALLCAP ROUNDUP: Wills & Co Declared In Default

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps WILLS & CO STOCKBROKERS LTD, a small cap share dealer, has been declared to be in default by the Financial Services Compensation Scheme, four months afte

Read more
1 Jul 2010 12:57

UPDATE: Allergy Therapeutics Buys Swiss Co In Europe Push

(Adds analyst comment, detail.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Allergy Therapeutics PLC (AGY.LN) Thursday said it agreed to buy its Swiss distributor, in one of its first steps in a new strategy to bolster its position in Europe. Allergy sa

Read more
1 Jul 2010 10:17

Allergy Therapeutics Buys Teomed For GBP700,000

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN) said Thursday it has agreed to acquire Teomed AG of Switzerland for a consideration of GBP700,000. MAIN FACTS: -The consideration for the acquisition of Teomed will comprise an initial cash payment of GBP500,000 on signing and a deferred

Read more
1 Jul 2010 10:04

Allergy Therapeutics Acquisition

TIDMAGY RNS Number : 6201O Allergy Therapeutics PLC 01 July 2010 ? Thursday 1 July 2010 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Allergy Therapeutics to acquire Teomed AG Expands Eur

Read more
24 Mar 2010 16:49

Cairn boss raises nearly £3m

Cairn Energy chief executive Sir Bill Gammell has raised nearly £3m from a share sale. Sir Bill sold 721,042 shares in the oil and gas producer and explorer at 414.4p each. He retains 3.21m shares, which is equivalent to 0.23% of the company's share capital. There have been two other sales by Si

Read more
1 Mar 2010 11:04

Small caps round-up: Beowulf, E2V, Mobile Doctors...

Beowulf, owner of several exploration projects in Sweden, continues to believe in the commercial prospects for its asset portfolio which has increased in both quantity and quality as well as resource type. Losses grew to £520,000 in 2009 from £399,000 the year before, but it says future price tren

Read more
22 Sep 2009 06:47

Tuesday tips round-up: Alliance Trust, MP Evans, Allergy Therapeutics

Alliance Trust's investment stance means that it is always in danger of trailing more heavily geared rivals when the stock market runs sharply ahead. However, on a rolling total return basis it continues to fare well ? ranked first out of its six largest peers over both one and two years. Further,

Read more
21 Sep 2009 08:04

Allergy Therapeutics narrows interim loss

Allergy vaccination group Allergy Therapeutics narrowed half year losses and said it is well placed to capitalise on the investments of the past. Pre-tax losses narrowed to £11.44m in the six month ended 30 June compared with a loss of £20.24m last time. Revenues increased by 22% to £37.8m, on a

Read more
9 Jul 2009 08:17

Small caps round-up: MBL, Netplay, Playtech...

Big profits and a maiden dividend have sent entertainment products distributor MBL charging higher Thursday. The supplier of CDs, DVDS and games reported a 42% hike in pre-tax profit for the year ended 31 March 2009 to £8.1m on revenue up 77.5% to £143.6m. Its major competitor, Entertainment UK, t

Read more
8 Jul 2009 16:52

Booker directors cash in

A number of directors at Booker have sold millions worth of shares the same day as the cash and carry group said profits and net debt remain in line with expectations. Finance director Jonathan Prentis and operating director Bryn Satherley each made £2.63m, selling 7.5m shares at 35.00p. Commercia

Read more
12 Jun 2009 07:31

Consortium takes 50% of Allergy

A Latin American business group is to take control of hay fever treatment developer Allergy Therapeutics through the injection of £12.5m of new funds at 12p per share. Azure Ventures, an investment vehicle of the Weinstein family of Chile, whose interests include a group of pharmaceutical companies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.